Literature DB >> 15255807

Plasma concentrations during naltrexone implant treatment of opiate-dependent patients.

Linda Olsen1, Asbjørg S Christophersen, Grete Frogopsahl, Helge Waal, Jørg Mørland.   

Abstract

AIMS: To evaluate individual variations in plasma concentrations over time in patients with naltrexone implants.
METHODS: Ten opioid-dependent patients received up to four implants. Plasma samples were collected regularly for the analyses of naltrexone and the metabolite beta-naltrexol.
RESULTS: The median naltrexone C(max) was 12.3 (range 5.8-22.1) ng ml(-1), the median T(max) was 1 day (range 3 h to 35 days), and the median length of time that plasma concentrations were above 1 ng ml(-1) was 55 (range 30-80) days. Two patients reported heroin use without experiencing any effect. Tissue reactions were recorded in two patients after repeated implantation.
CONCLUSION: Marked individual and intraindividual variations in naltrexone concentrations were observed. Further studies should be performed to evaluate the need for therapeutic drug monitoring during naltrexone implant treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15255807      PMCID: PMC1884587          DOI: 10.1111/j.1365-2125.2004.02122.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Depot naltrexone: long-lasting antagonism of the effects of heroin in humans.

Authors:  Sandra D Comer; Eric D Collins; Herbert D Kleber; Elie S Nuwayser; James H Kerrigan; Marian W Fischman
Journal:  Psychopharmacology (Berl)       Date:  2001-11-01       Impact factor: 4.530

Review 2.  Naltrexone maintenance treatment for opioid dependence.

Authors:  U Kirchmayer; M Davoli; A Verster
Journal:  Cochrane Database Syst Rev       Date:  2001

3.  Implantable narcotic antagonists: a possible new treatment for narcotic addiction.

Authors:  C N Chiang; A Kishimoto; G Barnett; L E Hollister
Journal:  Psychopharmacol Bull       Date:  1985

4.  Clinical evaluation of a naltrexone sustained-release preparation.

Authors:  C N Chiang; L E Hollister; H K Gillespie; R L Foltz
Journal:  Drug Alcohol Depend       Date:  1985-09       Impact factor: 4.492

5.  The urinary excretion profile of naltrexone and metabolites in man.

Authors:  E J Cone; C W Gorodetzky; S Y Yeh
Journal:  Drug Metab Dispos       Date:  1974 Nov-Dec       Impact factor: 3.922

6.  Naltrexone: disposition, metabolism, and effects after acute and chronic dosing.

Authors:  K Verebey; J Volavka; S J Mulé; R B Resnick
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

7.  Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases.

Authors:  Colin Brewer
Journal:  Addict Biol       Date:  2002-07       Impact factor: 4.280

8.  Serum time course of naltrexone and 6 beta-naltrexol levels during long-term treatment in drug addicts.

Authors:  A Ferrari; M Bertolotti; A Dell'Utri; U Avico; E Sternieri
Journal:  Drug Alcohol Depend       Date:  1998-11-01       Impact factor: 4.492

Review 9.  Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

10.  Naltrexone treatment of heroin addiction: one-year follow-up.

Authors:  B A Judson; A Goldstein
Journal:  Drug Alcohol Depend       Date:  1984-07       Impact factor: 4.492

View more
  8 in total

1.  Advances in opioid antagonist treatment for opioid addiction.

Authors:  Walter Ling; Larissa Mooney; Li-Tzy Wu
Journal:  Psychiatr Clin North Am       Date:  2012-04-10

2.  Naltrexone-induced Nicolau syndrome masquerading as cutaneous abscess.

Authors:  Daniel Perli; Catharine Martone; Alwyn Rapose
Journal:  BMJ Case Rep       Date:  2012-12-14

Review 3.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 4.  Injectable and implantable sustained release naltrexone in the treatment of opioid addiction.

Authors:  Nikolaj Kunøe; Philipp Lobmaier; Hanh Ngo; Gary Hulse
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

5.  Pharmacological enhancement of naltrexone treatment for opioid dependence: a review.

Authors:  Paolo Mannelli; Kathleen S Peindl; Li-Tzy Wu
Journal:  Subst Abuse Rehabil       Date:  2011-06

Review 6.  Opioid Addiction: Social Problems Associated and Implications of Both Current and Possible Future Treatments, including Polymeric Therapeutics for Giving Up the Habit of Opioid Consumption.

Authors:  M Cristina Benéitez; M Esther Gil-Alegre
Journal:  Biomed Res Int       Date:  2017-05-18       Impact factor: 3.411

Review 7.  Naltrexone Implant for Opioid Use Disorder.

Authors:  Amber N Edinoff; Catherine A Nix; Claudia V Orellana; Samantha M StPierre; Erin A Crane; Blaine T Bulloch; Elyse M Cornett; Rachel L Kozinn; Adam M Kaye; Kevin S Murnane; Alan D Kaye
Journal:  Neurol Int       Date:  2021-12-30

Review 8.  Selective review and commentary on emerging pharmacotherapies for opioid addiction.

Authors:  Walter Ling; Larissa Mooney; Min Zhao; Suzanne Nielsen; Matthew Torrington; Karen Miotto
Journal:  Subst Abuse Rehabil       Date:  2011-10-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.